Quick Summary
Lormalzi 350mg Injection
Last updated on 26 Sep 2026 | 08:41 AM (IST)
₹83345
MRP: ₹91688
(You Save ₹8343)
1 VIAL(s)
Lormalzi 350mg Injection
Salt Composition
DONANEMAB
PAP Offer
Buy 1, Get 1 Free. Contact us for latest updates.
Marketer
ELI LILLY AND COMPANY INDIA PVT LTD
Prepaid Only. Non-Returnable.
9% OFF
₹83345
MRP: ₹91,688.00
Inclusive of all taxes
9% Off
Salt Composition
DONANEMAB
PAP Offer
Buy 1, Get 1 Free. Contact us for latest updates.
Marketer
ELI LILLY AND COMPANY INDIA PVT LTD
Prepaid Only. Non-Returnable.
Dispatch: Today
Care delivered without the wait. Your order is prioritized for rapid dispatch to ensure it reaches your doorstep on time.
Better Service Satisfied Customers
Introduction
Lormalzi 350mg injection contains the active constituent Donanemab, which belongs to the family of anti-amyloid monoclonal antibody medications. It works by targeting and clearing amyloid-beta plaques that build up in the brain. This injection is used for the treatment of Alzheimer's disease, specifically for adults with early symptomatic disease, including mild cognitive impairment and mild dementia stage of Alzheimer's disease.
Do not consume this medicine if allergic to Donanemab or any of its ingredients, as this can cause serious hypersensitivity reactions including anaphylaxis. Before starting treatment, your physician will recommend a baseline brain MRI, since this medicine can cause swelling or bleeding in the brain, known as ARIA, and patients with more than four cerebral microbleeds, cortical superficial siderosis, or a major vascular contribution to cognitive impairment may need to be excluded from treatment. Inform your doctor if you are on blood-thinning medicines, as this may increase certain risks during treatment. Testing for ApoE ε4 gene status before starting treatment is recommended to assess risk, since carriers with two copies of this gene have a higher incidence of ARIA. Notify your physician if you think you are pregnant, planning to get pregnant, or breastfeeding.
Uses
Uses of Lormalzi 350mg Injection
Early symptomatic Alzheimer's disease (mild cognitive impairment)
Mild dementia stage of Alzheimer's disease
How Lormalzi 350mg Injection Works
Lormalzi 350mg Injection works by binding to and clearing aggregated amyloid-beta plaques in the brain, which are believed to contribute to the progression of Alzheimer's disease. By reducing plaque burden, this medicine is intended to slow the decline in memory and thinking abilities in people with early Alzheimer's disease.
Interaction of Lormalzi 350mg Injection with other drugs
Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional or vitamin supplements, and herbal products you take or have taken before treatment. In particular, tell your doctor if you take anticoagulant (blood-thinning) medicines, as this may need to be factored into your treatment plan.
Storage
Keep Lormalzi 350mg Injection out of sight and reach of children.
Store refrigerated at 2°C to 8°C. Do not freeze or shake.
Keep the vial in the outer carton to protect from light.
If refrigeration is not available, the medicine may be stored at room temperature (20°C to 25°C) for up to 3 days.
How to take Lormalzi 350mg Injection
Lormalzi 350mg injection is administered as an intravenous infusion into the vein, once every four weeks. If this injection is recommended for you, a healthcare professional will give it. Do not self-administer. Your dose may be modified based on the reduction of amyloid plaques seen on amyloid PET imaging, or if ARIA occurs. If an infusion is missed, resume treatment as soon as possible, usually every 4 weeks at the same dose.
Safety Advice
Pregnancy
Before starting treatment, it is advised to talk with your doctor about whether taking Lormalzi 350mg injection during pregnancy is safe or unsafe.
Breast Feeding
There is no available data on the presence of Donanemab in human milk or its effects on breastfed infants or milk production. Consult your doctor before starting treatment.
Lungs
No specific lung-related warnings have been established with Lormalzi (donanemab). However, inform your doctor immediately if you develop new or worsening cough, shortness of breath, wheezing, or difficulty breathing during or after treatment, as these symptoms should be evaluated promptly
Liver
Donanemab is not generally associated with significant liver toxicity, although mild increases in liver enzymes have been reported. Inform your doctor if you have a history of liver disease or if you develop symptoms such as yellowing of the skin or eyes, dark urine, unusual fatigue, or abdominal pain during treatment.
Alcohol
It is unknown whether drinking alcohol while taking Lormalzi 350mg injection is safe. Please speak with your physician.
Driving
Some people may experience dizziness or confusion related to ARIA while taking Lormalzi 350mg injection, which may impair the ability to drive safely. Speak to your doctor if you experience such symptoms.
Side Effects
Side effects are unwanted symptoms caused by medicines. Although all medicines can cause side effects, not everyone experiences them.
Serious
Amyloid-related imaging abnormalities (ARIA) — temporary brain swelling or bleeding, which can be life-threatening
Serious allergic reactions including anaphylaxis and swelling of the face, lips, tongue, or throat
Infusion-related reactions with breathing difficulty or chest pain
Common
Headache
Chills, sweating, skin irritation, nausea
Infusion site redness or swelling
Expert Tips
Attend all scheduled MRI scans, as monitoring for ARIA is an essential part of treatment with Lormalzi 350mg injection. Contact your doctor right away if you notice changes in vision, confusion, dizziness, headache, nausea, or seizures. Inform your doctor if you consume any other medicine, particularly blood thinners. Keep all follow-up appointments so your doctor can monitor your response to treatment. Connect with your physician if you have any questions, doubts, or concerns about the medicine.
FAQs
Q1.
What is Lormalzi 350mg injection used for?
Lormalzi 350mg injection is used to treat early symptomatic Alzheimer's disease, including mild cognitive impairment and the mild dementia stage.
Q2.
What is ARIA, and should I be worried about it?
ARIA (amyloid-related imaging abnormalities) typically presents without symptoms but is monitored closely with MRI scans, as it can occasionally cause serious effects. Your doctor will schedule regular scans to monitor for this.
Q3.
How often will I need to take Lormalzi 350mg injection?
It is given as an intravenous infusion once every four weeks by a healthcare professional.
Q4.
Do I need any tests before starting Lormalzi 350mg injection?
Yes, a baseline brain MRI is recommended, and testing for ApoE ε4 gene status is advised to assess your risk of ARIA before starting treatment
Fact Box
Molecule name | Donanemab |
Therapeutic class | Anti-amyloid monoclonal antibody |
Pharmacological class | Amyloid-beta-directed antibody |
Indication: |
|
References
FDA Prescribing Information, KISUNLA (donanemab-azbt) injection, U.S. Food and Drug Administration, [Revised 2025], https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761248s004lbl.pdf
Drugs.com, Donanemab: Uses, Side Effects, Dosage, Warnings, [Accessed 2026], https://www.drugs.com/donanemab.html
Medscape Reference, Kisunla (donanemab) dosing, indications, interactions, adverse effects, https://reference.medscape.com/drug/kisunla-donanemab-4000315
Mayo Clinic, Donanemab-azbt (intravenous route) — Side effects & uses, https://www.mayoclinic.org/drugs-supplements/donanemab-azbt-intravenous-route/description/drg-20571313
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr Arathy J S
BDS
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 26 Sep 2026 | 08:41 AM (IST)
Want to know more?
Read Our Editorial Policy